Tjasa Hranjec, Michael Estreicher, Bradley Rogers, Lisa Kohler, Rachele Solomon, Sara Hennessy, Megan Cibulas, Deborah Hurst, Mohamed Hegazy, Jieun Lee, Donny Perez, Norman Doctor, Chauniqua Kiffin, Danielle Pigneri, Heather LaGuardia, Kathryn Shaw, Juan Arenas, Andrew Rosenthal, Randy S Katz, Robert G Sawyer, Paul E Pepe
OBJECTIVES: Coagulopathy of coronavirus disease 2019 is largely described as hypercoagulability, yet both thrombotic and hemorrhagic complications occur. Although therapeutic and prophylactic anticoagulant interventions have been recommended, empiric use of antifactor medications (heparin/enoxaparin) may result in hemorrhagic complications, including death. Furthermore, traditional (antifactor) anticoagulation does not address the impact of overactive platelets in coronavirus disease 2019...
December 2020: Critical care explorations